Division of Translational Vaccine Research, City of Hope National Medical Center, Duarte, California, USA.
Cancer Invest. 2011 Oct;29(8):501-10. doi: 10.3109/07357907.2011.606248. Epub 2011 Aug 15.
The p53 gene product is an attractive target for tumor immunotherapy. The present study aims to understand the potential of MVAp53 vaccine to induce expansion of p53-specific cytotoxic T lymphocyte ex vivo in cancer patients. The result indicated that 14 of 23 cancer patients demonstrated p53-specific IFN-γ production, degranulation, cell proliferation, and lysis of p53 overexpressed human tumor cell lines. These experiments show that MVAp53 stimulation has the potential to induce the expansion of p53-specific cytotoxic T lymphocyte from the memory T cell repertoire. The data suggest that MVAp53 vaccine is an ideal candidate for cancer immunotherapy.
p53 基因产物是肿瘤免疫治疗的一个有吸引力的靶标。本研究旨在探讨 MVAp53 疫苗在体外诱导癌症患者中 p53 特异性细胞毒性 T 淋巴细胞扩增的潜力。结果表明，23 例癌症患者中有 14 例表现出 p53 特异性 IFN-γ 产生、脱颗粒、细胞增殖和 p53 过表达的人肿瘤细胞系的裂解。这些实验表明，MVAp53 刺激有可能从记忆 T 细胞库中诱导 p53 特异性细胞毒性 T 淋巴细胞的扩增。数据表明，MVAp53 疫苗是癌症免疫治疗的理想候选者。
